The Food and Drug Administration has signed off on Optune Pax, a wearable device that uses alternating electrical fields to treat adults with locally advanced, inoperable pancreatic cancer. The clearance, announced this week, follows a large Phase 3 study showing that adding the device to standard chemotherapy produced a modest but statistically significant survival benefit. For people who cannot have surgery, doctors and advocates say this is the first meaningful new treatment option for this stage of the disease in roughly 30 years.
What the FDA approved
The agency granted premarket approval to Optune Pax as a first-of-its-kind, noninvasive system that delivers tumor-treating fields (TTFields) to the abdomen through adhesive transducer arrays connected to a small, portable generator. According to the U.S. Food and Drug Administration, the decision was based on randomized data showing that when the device was used with gemcitabine and nab-paclitaxel chemotherapy, overall survival was extended by about two months compared with chemotherapy alone.
What the PANOVA-3 trial showed
The Phase 3 PANOVA-3 study enrolled 571 patients and met its primary endpoint: median overall survival reached 16.2 months in the group that received Optune Pax plus chemotherapy, versus 14.2 months for those on chemotherapy alone (hazard ratio 0.82; p=0.039). As detailed by Novocure, the trial also found improved one-year survival and roughly a six-month delay in time to pain progression, without adding systemic chemotherapy toxicity.
Voices from regulators
FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that the pancreatic cancer community deserves better options. The agency also highlighted the device’s potential to support more patient-centered care outside traditional clinic walls, according to the FDA.
Safety, training and eligibility
Novocure and trial investigators reported that the device was generally well tolerated, although skin reactions under the arrays were common. About three-quarters of treated patients experienced device-related skin adverse events, and a smaller share, about 7.7%, had Grade 3 or higher reactions. Novocure notes that Optune Pax should be used only after training by qualified staff and is not appropriate for people with certain electrical implants or with severe sensitivity to the adhesive gels used with the transducer arrays.
What this means locally
Local coverage arrived quickly. CBS New York pointed out that this marks the first new option for inoperable pancreatic cancer in about 30 years. Patients and caregivers are being urged to talk with their oncology teams about eligibility, timing and possible side effects, and to ask whether their treatment center will offer the device or can connect them with Novocure’s training and support services.
.jpg){kind=link}